Otsuka Tries To Halt Alkermes Ride On Abilify’s Coattails
This article was originally published in PharmAsia News
FDA should not review or approve Alkermes’ NDA for aripiprazole lauroxil because it is based on only one adequate and well-controlled clinical trial, Otsuka argues.
You may also be interested in...
Boehringer’s anticoagulant Pradaxa adds DVT/PE claim, coming closer to labeling parity with market leader Xarelto; Bristol gets in on the race for new oral hepatitis C drugs with daclatasvir/asunaprevir filings; Genzyme reaches agreement with FDA on resubmission plan for Lemtrada; and Alkermes prepares to file its long-acting aripiprazole lauroxil.
Building on its experience in long-acting injectables, Alkermes is preparing to file an NDA for its long-acting version of Otsuka/Bristol-Myers Squibb’s antipsychotic Abilify in 2014.
Two settlements totaling $729m resolve kickback claims related to speaker programs and copay charities; Novartis will limit payments to healthcare professionals for providing medical education under a new corporate integrity agreement.